Mycovia Pharmaceuticals Announces U.S. FDA Acceptance and Priority Review of New Drug Application for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

 DURHAM, N.C.--(BUSINESS WIRE) July 28, 2021 --Mycovia Pharmaceuticals, Inc. (Mycovia), an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news